Comparative efficacy and tolerance of centrally acting muscle relaxants in elderly patients with nonspecific musculoskeletal pain
https://doi.org/10.14412/2074-2711-2020-1-39-44
Abstract
Objective: to evaluate the clinical efficacy and tolerability of the Russian drug tolperisone (calmyrex) versus tizanidine and baclofen in the therapy of acute nonspecific musculoskeletal pain (NSMSP) in the elderly.
Patients and methods. Examinations were made in 135 elderly (60–75-year-old) patients with acute NSMSP. To relieve pain syndrome, all the patients were prescribed nimesulide suspension 100 mg twice a day after meals. The patients were randomized using an envelope method to three groups, each of which took a muscle relaxant as tablets for 15 days: Group 1 received the Russian drug tolperisone (calmyrex) 150 mg thrice a day; Group 2 used tizanidine 2 mg thrice a day; Group 3 had baclofen 10 mg twice a day. Pain syndrome was rated on a visual analogue scale (VAS). To measure orthostatic blood pressure, to check the coordinator system, and to record adverse events (AEs) were mandatory.
Results and discussion. At 15 days, treatment substantially reversed pain syndrome according to VAS scores in all the groups: from 68 to 14 in Group 1, from 64 to 17 in Group 2, and from 62 to 18 in Group 3 (without significant differences between the groups). AEs were more common in Groups 2 and 3 patients who received tizanidine or baclofen. Orthostatic hypotension was reported in 3 patients taking baclofen. The high safety and good tolerability of a combination of a non-steroidal anti-inflammatory drug (NSAID) and a muscle relaxant were noted in the calmyrex group.
Although muscle relaxants ensure clinically significant short-term pain relief in acute nonspecific back pain, it is necessary to take into account that elderly patient can develop AEs when taking the drugs, which is associated with delayed metabolic reactions, reduced hepatic blood flow and glomerular filtration rate, and a larger number of diseases and used medications.
Conclusion. Therapy with NSAIDs and centrally acting muscle relaxants for acute NSMSP in elderly people calls for special precautions due to the fact that there may be AEs that are less likely to occur with calmyrex than with tizanidine and baclofen.
Patients and methods. Examinations were made in 135 elderly (60–75-year-old) patients with acute NSMSP. To relieve pain syndrome, all the patients were prescribed nimesulide suspension 100 mg twice a day after meals. The patients were randomized using an envelope method to three groups, each of which took a muscle relaxant as tablets for 15 days: Group 1 received the Russian drug tolperisone (calmyrex) 150 mg thrice a day; Group 2 used tizanidine 2 mg thrice a day; Group 3 had baclofen 10 mg twice a day. Pain syndrome was rated on a visual analogue scale (VAS). To measure orthostatic blood pressure, to check the coordinator system, and to record adverse events (AEs) were mandatory.
Results and discussion. At 15 days, treatment substantially reversed pain syndrome according to VAS scores in all the groups: from 68 to 14 in Group 1, from 64 to 17 in Group 2, and from 62 to 18 in Group 3 (without significant differences between the groups). AEs were more common in Groups 2 and 3 patients who received tizanidine or baclofen. Orthostatic hypotension was reported in 3 patients taking baclofen. The high safety and good tolerability of a combination of a non-steroidal anti-inflammatory drug (NSAID) and a muscle relaxant were noted in the calmyrex group.
Although muscle relaxants ensure clinically significant short-term pain relief in acute nonspecific back pain, it is necessary to take into account that elderly patient can develop AEs when taking the drugs, which is associated with delayed metabolic reactions, reduced hepatic blood flow and glomerular filtration rate, and a larger number of diseases and used medications.
Conclusion. Therapy with NSAIDs and centrally acting muscle relaxants for acute NSMSP in elderly people calls for special precautions due to the fact that there may be AEs that are less likely to occur with calmyrex than with tizanidine and baclofen.
About the Authors
R. V. Gorenkov
Higher School of Health Management, Institute of Healthcare Leadership and Management, I.M. Sechenov First Moscow State Medical University (Sechenov University), Ministry of Health of Russia
Russian Federation
8, Trubetskaya St., Build. 2, Moscow 119991
Russian Federation
8, Trubetskaya St., Build. 2, Moscow 119991
M. N. Dadasheva
M.F. Vladimirsky Moscow Regional Research Clinical Institute
Russian Federation
61/2, Shchepkin St., Build. 1, Moscow 129110
Russian Federation
61/2, Shchepkin St., Build. 1, Moscow 129110
I. A. Zolotovskaya
Samara State Medical University, Ministry of Health of Russia
Russian Federation
89, Chapaevskaya St., Samara 443099
Russian Federation
89, Chapaevskaya St., Samara 443099
V. A. Kruglov
M.F. Vladimirsky Moscow Regional Research Clinical Institute
Russian Federation
61/2, Shchepkin St., Build. 1, Moscow 129110
Russian Federation
61/2, Shchepkin St., Build. 1, Moscow 129110
References
1. Patel K, Guralnik J, Dansie E, Turk D. Prevalence and impact of pain among older adults in the United States: Findings from the 2011 National Health and Aging Trends Study. Pain. 2013 Dec;154(12):2649-57. doi: 10.1016/j.pain.2013.07.029.
2. Yakhno NN, Kukushkin ML, editors. Bol'. Prakticheskoe rukovodstvo dlya vrachei [Pain. Practical guide for doctors]. Moscow: Izdatel'stvo RAMN; 2011. 565 p.
3. Weiner DK, Fang M, Gentili A, et al. Deconstructing chronic low back pain in the older adult-step by step evidence and expertbased recommendations for evaluation and treatment. Part I: Hip osteoarthritis. Pain Med. 2015 May;16(5):886-97. doi: 10.1111/pme.12757. Epub 2015 Apr 3.
4. Parfenov VA, Yakhno NN, Kukushkin ML, et al. Acute nonspecific (musculoskeletal) low back pain Guidelines of the Russian Society for the Study of Pain (RSSP). Nevrologiya, neiropsikhiatriya, psikhosomatika = Neurology, Neuropsychiatry, Psychosomatics. 2018;10(2):4–11. (In Russ.). doi: 10.14412/2074-2711-2018-2-4-11
5. Kim S, Lee T, Lim S. Prevalence of Disc Degeneration in Asymptomatic Korean Subjects. Part 1: Lumbar Spine. J Korean Neurosurg Soc. 2013 Jan;53(1):31-8. doi: 10.3340/jkns.2013.53.1.31. Epub 2013 Jan 31.
6. Treede RD, Jensen TS, Campbell JN, et al. Neuropathic pain: redefinition and a grading system for clinical and research purposes. Neurology. 2008 Apr 29;70(18):1630-5. Epub 2007 Nov 14.
7. Lisi AJ, Breuer P, Gallagher RM, et al. Deconstructing chronic low back pain in the older adult-step by step evidence and expertbased recommendations for evaluation and treatment. Part II: Myofascial pain. Pain Med. 2015 Jul;16(7):1282-9. doi: 10.1111/pme.12821. Epub 2015 Jun 18.
8. Fatemi G, Fang MA, Breuer P, et al. Deconstructing chronic low back pain in the older adult-step by step evidence and expertbased recommendations for evaluation and treatment. Part III: Fibromyalgia syndrome. Pain Med. 2015 Sep;16(9):1709-19. doi: 10.1111/pme.12863. Epub 2015 Aug 14.
9. Carley JA, Karp JF, Gentili A, et al. Deconstructing chronic low back pain in the older adult-step by step evidence and expertbased recommendations for evaluation and treatment. Part IV: Depression. Pain Med. 2015 Nov; 16(11):2098-108. doi: 10.1111/pme.12935. Epub 2015 Nov 5.
10. DiNapoli EA, Craine M, Dougherty P, et al. Deconstructing chronic low back pain in the older adult-step by step evidence and expertbased recommendations for evaluation and treatment. Part V: Maladaptive coping. Pain Med. 2016 Jan;17(1):64-73. doi: 10.1093/pm/pnv055.
11. Karateev AE, Nasonov EL, Yakhno NN, et al. Clinical guidelines «Rational use of nonsteroidal anti-inflammatory drugs (NSAIDs) in clinical practice». Sovremennaya revmatologiya = Modern Rheumatology Journal. 2015;(1):4–23. (In Russ.). doi: 10.14412/1996-7012-2015-1-4-23
12. Xu S, Rouzer CA, Marnett LJ. Oxicams, a class of nonsteroidal anti-inflammatory drugs and beyond. IUBMB Life. 2014 Dec; 66(12):803-11. doi: 10.1002/iub.1334. Epub 2014 Dec 23.
13. van Tulder MW, Touray T, Furlan AD, et al; Cochrane Back Review Group (2003). Muscle relaxants for nonspecific low back pain: A systematic review within the framework of the cochrane collaboration. Spine (Phila Pa 1976). 2003 Sep 1;28(17):1978-92.
14. Kukushkin ML. Algorithms for diagnosis and treatment of patients with back pain. Rossiiskii zhurnal boli. 2014:(3–4):3-6. (In Russ.).
15. Pavlenko SS. Boli v nizhnei chasti spiny (epidemiologiya, kliniko-diagnosticheskaya klassifikatsiya, sovremennye napravleniya v diagnostike, lechenii i standartizatsii meditsinskoi pomoshchi) [Lower back pain (epidemiology, clinical and diagnostic classification, current trends in diagnosis, treatment and standardization of medical care]. Novosibirsk: Sibmedizdat NGMU; 2007. 172 p.
16. Mafi JN, McCarthy EP, Davis RB, Landon BE. Worsening trends in the management and treatment of back pain. JAMA Intern Med. 2013 Sep 23;173(17):1573-81. doi: 10.1001/jamainternmed.2013.8992.
17. Chiba L, Zhusupova AS, Likhachev SA, et al. Systematic review of the use of muscle relaxants in the treatment of low back pain. Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova. 2018; 118(12):100-13. (In Russ.).
18. Weiner DK, Gentili A, Rossi M, et al. Aging Back Clinics-a Geriatric Syndrome Approach to Treating Chronic Low Back Pain in Older Adults: Results of a Preliminary Randomized Controlled Trial. Pain Med. 2019 Sep 10. pii: pnz179. doi: 10.1093/pm/pnz179. [Epub ahead of print].
19. Pareek A, Chandurkar N, Chandanwale AS, et al. Aceclofenac–tizanidine in the treatment of acute low back pain: a double-blind, doubledummy, randomized, multicentric, comparative study against aceclofenac alone. Eur Spine J. 2009 Dec;18(12):1836-42. doi: 10.1007/s00586-009-1019-4. Epub 2009 May 7.
20. Kiel LB, Hoegberg LC, Jansen T, et al. A Nationwide Register Based Survey of Baclofen Toxicity. Basic Clin Pharmacol Toxicol. 2015 May;116(5):452-6. doi:10.1111/bcpt.12344. Epub 2014 Nov 22.
21. Montastruc J, Laborie I, Bagheri H, Senard M. Drug-induced orthostatic hypotension: A five-year experience in a regional pharmacovigilance centre in France. Clin Drug Invest.1997;14(1):61-65.
22. Ostroumova OD, Chernyaeva MS, Petrova MM, Golovina OV. Orthostatic hypotension: definition, pathophysiology, classification, prognostic aspects, diagnosis and treatment. Ratsional'naya farmakoterapiya v kardiologii. 2018;14(5):747-56. (In Russ.).
23. Sonnesyn H, Nilsen DW, Rongve A, et al. High prevalence of orthostatic hypotension in mild dementia. Dement Geriatr Cogn Disord. 2009;28(4):307-13. doi: 10.1159/000247586. Epub 2009 Oct 14.
24. Khabirov FA. Rukovodstvo po klinicheskoi nevrologii pozvonochnika [Guide to clinical neurology of the spine]. Kazan'; 2006. 518 p..
25. See S, Ginzburg R. Choosing a Skeletal Muscle Relaxant. Am Fam Physician. 2008 Aug 1;78(3):365-70.
Review
Supporting agencies: Публикация статьи поддержана ЗАО «ФармФирма «Сотекс».
For citations:
Gorenkov R.V., Dadasheva M.N., Zolotovskaya I.A., Kruglov V.A. Comparative efficacy and tolerance of centrally acting muscle relaxants in elderly patients with nonspecific musculoskeletal pain. Neurology, Neuropsychiatry, Psychosomatics. 2020;12(1):39-44. (In Russ.) https://doi.org/10.14412/2074-2711-2020-1-39-44
Views: 2401
Email this article 